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Summary
Objectives—To determine the diagnostic accuracy of World Health Organization (WHO) 2010
and 2006 as well as United States Department of Health and Human Services (DHHS) 2008
definitions of immunological failure for identifying virological failure in children on antiretroviral
therapy (ART).
Methods—Analysis of data from children (<16 years at ART initiation) at South African ART
sites at which CD4 count/percent and HIV-RNA monitoring are performed 6-monthly. Incomplete
virological suppression (IVS) was defined as failure to achieve ≥1 HIV-RNA ≤400 copies/mL
between 6 and 15 months on ART and viral rebound (VR) as confirmed HIV-RNA ≥5000 copies/
mL in a child on ART for ≥18 months who had achieved suppression during the first year on
treatment.
Results—Among 3115 children (median (IQR) age 48 (20-84) months at ART initiation) on
treatment for ≥1 year, sensitivity of immunological criteria for IVS was 10%, 6% and 26% for
WHO 2006 2010 and DHHS 2008 criteria respectively. The corresponding positive predictive
values (PPV) were 31% 20% and 20%. Diagnostic accuracy for VR was determined in 2513
children with ≥18 months of follow-up and virological suppression during the first year on ART
with sensitivity of 5% (WHO 2006/2010) and 27% (DHHS 2008). PPV results were 42% (WHO
2010), 43% (WHO 2006) and 20% (DHHS 2008).
Conclusion—Current immunological criteria are unable to correctly identify children failing
ART virologically. Improved access to viral load testing is needed to reliably identify virological
failure in children.
*Corresponding author: University of Cape Town Faculty of Health Sciences, Anzio Road, Observatory, 7925, Cape Town, South
Africa. Phone: +27 21 4066051; Fax: +27 21 4066764; mary-ann.davies@uct.ac.za.
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Introduction
Poor access to viral load testing in resource-limited settings results in reliance on
immunological criteria to identify treatment failure in patients on antiretroviral therapy
(ART). Studies in adults have shown limited value of immunological criteria to detect
virological failure (VF) (Keiser et al. 2009, Mee et al. 2008, Badri et al. 2008). While low
sensitivity of immunological criteria for identifying VF could result in delayed switching to
second-line treatment with accumulation of resistance mutations, low positive predictive
value (PPV) may incorrectly identify patients as needing second-line treatment when they
are virologically suppressed. The few paediatric studies of diagnostic accuracy of
immunological criteria for VF are limited by small cohort size and/or VF definition based on
single elevated HIV-RNA measurements (Ruel et al. 2010, Jittamala et al. 2009, Emmett et
al. 2010). We analysed data from routine pediatric ART clinics to determine the diagnostic
accuracy of WHO (2006, 2010) and United States Department of Health and Human
Services (DHHS) 2008 (National Institutes of Health 2008) criteria for immunological
failure for identifying (i) incomplete viral suppression during the first year on ART and (ii)
confirmed viral rebound.
Methods
Data was collected prospectively from ART-naïve children (<16 years at ART start)
initiating ≥3 antiretrovirals at South African sites participating in IeDEA-Southern Africa
(IeDEA-SA, see www.iedea-sa.org), all of which had CD4 and HIV-RNA measurements
performed 6-monthly. The characteristics of these sites have been described previously
(Davies et al. 2009). Each site has institutional ethical approval to contribute data to IeDEA
analyses.
HIV-RNA was measured using Amplicor 1.5 (Roche Diagnostics) or NucliSens EasyQ
assays (bioMerieux), with good comparability (Stevens et al. 2005). CD4 measurements
were performed using standard dual platform flow cytometry or the single platform
PanLeucogated method (Glencross et al. 2008). We defined incomplete virological
suppression (IVS) as failure to achieve ≥1 HIV-RNA ≤400 copies/mL between 6 and 15
months on ART and viral rebound (VR) as confirmed HIV-RNA ≥5000 copies/mL in a
child on ART for ≥18 months whose HIV-RNA had suppressed during the first year on
treatment. We examined the following immunological criteria: WHO 2010: No definition
for children <2 years; CD4%<10% or CD4<200 cells/mm3 (age 2-4 years); CD4<100 cells/
mm3 (age ≥5 years) (WHO 2010). WHO 2006: No definition for children <1 year;
CD4%<15% (age 1-2 years); CD4%<10% (age 3-4 years); CD4<100 cells/mm3 (age ≥5
years) (WHO 2006). DHHS: During first year on ART: <5 percentage point CD4% increase
from baseline (CD4%<15 and age <5 years at baseline) or <50 cells/mm3 CD4 increase
from baseline (CD4<200 cells/mm3 and age ≥5 years at baseline); decline of CD4% by 5
percentage points from previous value, confirmed at subsequent measurement (<365 days
after first low value) (any age); return of CD4 count ≤baseline value (age ≥5 years at
baseline) (National Institutes of Health 2008).
For IVS, we assessed the diagnostic accuracy of never achieving a CD4 above the
immunological thresholds between 6 and 15 months on ART for identifying a child who
never had HIV-RNA ≤400 copies/mL during the same period. Only children followed up for
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≥1 year with ≥1 HIV-RNA measurement between 6 and 15 months were included. For VR,
CD4 and HIV-RNA measurements were carried forward for up to 3 months where tests
were performed asynchronously. For each unique paired CD4 and HIV-RNA measurement,
we determined the diagnostic value of CD4-based criteria for VR, using robust standard
errors to account for multiple measures per patient. Immunological results for which there
was still no concurrent virological diagnosis after carrying forward results, were not
evaluated. Further, the last immunological result before the end of follow-up/data base
closure was excluded to ensure that there was sufficient follow-up to for a confirmatory low
viral load measurement to have been done. Separate sensitivity analyses were performed
requiring either consecutive (within 365 days) CD4 measurements meeting immunological
criteria or using an HIV-RNA threshold of 1000 copies/mL to define confirmed VR.
Results
Of 3640 children with ≥1 year of follow-up, 3115 (86%) had ≥1 HIV-RNA measurement
between 6 and 15 months on ART. At ART initiation, median (interquartile range (IQR))
age was 48 (20-84) months. Most children were severely ill at ART initiation: 81% had
WHO-defined severe immune suppression (n=2911) and 68% of children had WHO Clinical
Stage 3/4 disease (n=2294) (WHO 2006). In keeping with South African guidelines
recommending protease inhibitor- (PI-) based first-line therapy in children <3 years old
(National Department of Health South Africa 2005), 35% of children were on PI-based first-
line treatment with non-nucleoside reverse transcriptase-based therapy in the remainder. IVS
occurred in 12.6% of children and sensitivity of immunological criteria for identifying IVS
ranged from 6% (WHO 2010) to 26% (DHHS) and PPV from 20% (WHO 2010 and DHHS)
to 31% (WHO 2006) (Table 1 (a)).
The accuracy of immunological criteria for identifying VR was assessed in 2513 children
with at least ≥18 months follow-up on ART whose HIV-RNA had suppressed during the
first year on treatment. The cumulative probability of viral rebound in the following 2 years
(by 42 months since ART start) was 5.5% (95% CI: 4.2-7.1). Requiring consecutive CD4
counts to meet immunological criteria increased PPV only slightly at the expense of
sensitivity, without any improvement in the area under the receiver operating characteristic
curve (Table 1 (b)).Sensitivity of immunological criteria for identifying VR ranged from 5%
(WHO 2006/2010) to 27% (DHHS) and PPV from 20% (DHHS) to 43% (WHO 2006)
(Table 1(b)). Lowering the VR threshold to 1000 copies/mL and using confirmed CD4
values to define immunological criteria yielded sensitivity (95%CI) of 2% (0-5%) (WHO
2006); 2% (0-4%) (WHO 2010) and 14% (8-19%) (DHHS); and PPV (95% CI) of 90%
(72-100%) (WHO 2006); 89% (68-100%) (WHO 2010) and 38% (26-50%) (DHHS).
Discussion
In this large longitudinal study we found that sensitivity and PPV were low for identifying
VF using WHO and DHHS immunological criteria. For example, using confirmed HIV-
RNA ≥5000 copies/mL after initial virological suppression to define VR, sensitivity was
only 4% using either WHO 2006 or 2010 criteria. Fewer than half of children meeting WHO
2006/2010 criteria would have HIV-RNA ≥5000 copies/mL.
These results concur with those of previous small studies from resource-limited settings.
Among 116 children in Uganda 20 (17%) had sustained viraemia (≥400 copies/mL) beyond
24 weeks on ART (Ruel et al. 2010). Only 2 of these ever met WHO 2006 immunological
criteria, and did so after >550 days of viraemia, while none met WHO 2010 criteria (Ruel et
al. 2010). Similarly, in a cross-sectional study of 206 children in Tanzania on ART for a
median duration of 2.4 years, 32% had a single HIV-RNA ≥400 copies/mL (Emmett et al.
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2010). WHO 2006 clinical and immunological failure criteria combined had a PPV of 100%
but identified only 3.5% of children with HIV-RNA ≥400 copies/mL (Emmett et al. 2010).
In Thailand, the sensitivity and PPV of DHHS immunological criteria for identifying
children with a single HIV-RNA >1000 copies/mL was 15% and 16% respectively
(Jittamala et al. 2009).
The poor sensitivity of immunological criteria for identifying VF is disappointing, however
perhaps an even greater concern is preventing the incorrect diagnosis of treatment failure in
a virologically suppressed child, with unnecessary switch to second-line treatment, hence the
importance of PPV. While PPV reached 89% for identifying VR ≥1000 copies/mL using a
confirmed CD4 value meeting WHO 2010 criteria, given that the WHO 2010 guidelines
HIV-RNA threshold for switching to second-line is 5000 copies/ml, in most instances the
number of false positives using immunological criteria is unacceptably high. Further,
absence of immunological failure on ART provides no assurance that a child is virologically
suppressed and not accumulating resistance mutations, and even high CD4 thresholds (e.g.
DHHS criteria) have low sensitivity for VF (PENPACT1 Study Team 2011). Improved
access to VL monitoring both to assess adherence and identify VF is therefore needed (Ford
& Calmy 2010, Wilson et al. 2009).
There are several limitations to this analysis of routinely collected data. Missing baseline
CD4 values limited evaluation of DHHS criteria. Baseline CD4 values are often unavailable
to clinicians if children initiate ART on clinical criteria, records are lost or a child changes
treatment site after ART initiation, highlighting the value of simple criteria using current or
recent measurements. The accuracy of WHO 2006 and 2010 criteria could not be evaluated
in children <1 and <2 years old respectively. Work-up bias may occur if either the reference
(HIV-RNA) or index (CD4) tests are not applied consistently (Whiting et al. 2004). In
particular, rigorous confirmation of low CD4 values is seldom done in South Africa, due to
access to HIV-RNA measurements to diagnose treatment failure. Exclusion of intercurrent
illness as a cause of low CD4, as advised in WHO guidelines (WHO 2010), was not possible
due to limited data on episodes of clinical illness. Immunological criteria may have
performed better if only low CD4 counts not explained by intercurrent illness had been
considered. PPV is dependent on the VF incidence in different programs, however the
incidence in this cohort was similar to that of other studies (Davies et al. 2011, Jittamala et
al. 2009, Kamya et al. 2007).
In summary, our results suggest that current immunological criteria are unable to correctly
identify children failing ART virologically. Improved access to viral load testing appears to
be the only feasible approach at this stage for reliably identifying VF in children on ART.
There are several existing technologies for the measurement of viral load (Stevens and
Marshall 2010) and expanded access should be supported by governments and donors.
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Table 1(a)
Diagnostic value of immunological criteria for identifying children with incomplete viral suppression during
first year on ART
Comparison of immunological failure diagnosis
(based on highest CD4 between 6 and 15 months on
ART)
with failure of viral suppression in same period
Comparison of immunological failure diagnosis
(based on highest CD4 between 6 and 15 months on
ART
and confirmed on a subsequent measurement)
with failure of viral suppression in same period
WHO 2006† WHO 2010§ USA WHO 2006† WHO 2010§ USA
Number of children (%) 90/2714 (3.3) 61/2380 (2.6) 355/2585 (13.7) 13/2502 (0.5) 9/2217 (0.4) 72/2277 (3.2)
Number of children with
paired data*
2581 2256 2470 2405 2126 2190
Sensitivity (%) 10 (7 - 14) 6 (3 - 10) 26 (21 - 31) 2 (0 - 4) 2 (0 - 4) 9 (5 - 12)
Specificity (%) 97 (97 - 98) 98 (97 - 98) 87 (86 - 89) 99 ( 99 - 100) 99 (99 - 100) 97 (97 - 98)
PPV (%) 31 (22 - 41) 20 (10 - 30) 20 (16 - 24) 38 (8 - 69) 33 (0 - 72) 27 (16 - 38)
NPV (%) 90 (89 - 91) 92 (91 - 93) 91 (89 - 92) 90 (89 - 91) 92 (91 - 93) 90 (89 - 92)
Number true positives 28 12 69 5 3 19
Number true negatives 2242 2017 1928 2151 1945 1916
Number false negatives 250 179 197 241 172 204
Number false positives 61 48 276 8 6 51
LR + 3.8 2.7 2.07 5.49 5.57 3.29
LR − 0.92 0.95 0.85 0.98 0.99 0.94
Area under ROC curve 0.537 0.520 0.567 0.508 0.507 0.530
*Number of children with paired data (both CD4 and HIV-RNA measures available and CD4 criteria evaluable in terms of immunological criteria)
differs for different definitions because of different age and data requirements for each definition
†Only determined for children>12 months of age
§Only determined for children>24 months of age
PPV = positive predictive value; NPV = negative predictive value; LR + = likelihood ratio of a positive test; LR − = likelihood ratio of a negative
test; ROC = receiver operating characteristic
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Table 1(b)
Diagnostic value of immunological criteria for identifying children with viral rebound
Comparison of immunological failure diagnosis
(based on single CD4 measure meeting criteria)
with confirmed HIV-RNA >5,000 copies/ml
Comparison of immunological failure diagnosis
(based on consecutive CD4 measure meeting criteria
with confirmed HIV-RNA >5,000 copies/ml
WHO 2006 WHO 2010§ USA WHO 2006 WHO 2010§ USA
Cumulative probability by
2 years 2.2% (1.5 - 3.2) 2.3% (1.5 - 3.3)
28.1% (25.2 -
31.3) 0.4% (0.2 - 1.0) 0.3% (0.1 - 0.9) 10.4% (8.6 -12.6)
Number of evaluable
pairs of data*
2499 2593 2191 2395 2507 2110
Sensitivity (%) 5 (2 - 9) 5 (2 - 9) 27 (19 -35) 2 (0 - 5) 2 (0 - 4) 13 (6 - 21)
Specificity (%) 99 (99 - 100) 99 (99 - 100) 88 (86 - 90) 100 (99 - 100) 100 (99 - 100) 95 (94 - 96)
PPV (%) 43 (23 - 63) 42 (22-61) 20 (13 - 26) 50 (19 - 81) 44 (14 - 75) 21 (10 - 32)
NPV (%) 91 (89 - 93) 91 (89 - 93) 92 (90 - 94) 91 (89 - 93) 91 (89 - 93) 91 (89 - 93)
Number true positives 13 13 58 5 4 26
Number true negatives 2245 2327 1740 2168 2269 1816
Number false negatives 224 235 157 217 229 172
Number false positives 17 18 236 5 5 96
LR + 7.3 6.83 2.26 9.79 7.81 2.62
LR − 0.95 0.95 0.83 0.98 0.98 0.91
Area under ROC curve 0.524 0.522 0.575 0.51 0.508 0.541
*
Paired data created from carrying forward asynchronously measured CD4 and HIV-RNA results for up to 3 months; Number of children with
paired data definitions because of different age and data requirements for each definition
§Only determined for children>24 months of age
PPV = positive predictive value; NPV = negative predictive value; LR + = likelihood ratio of a positive test; LR − = likelihood ratio of a negative
test; ROC = re characteristic
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